Share This Page
Drug Price Trends for DEXLANSOPRAZOLE DR
✉ Email this page to a colleague
Average Pharmacy Cost for DEXLANSOPRAZOLE DR
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| DEXLANSOPRAZOLE DR 30 MG CAP | 24979-0001-06 | 4.66112 | EACH | 2026-03-18 |
| DEXLANSOPRAZOLE DR 60 MG CAP | 62332-0824-90 | 4.21355 | EACH | 2026-03-18 |
| DEXLANSOPRAZOLE DR 30 MG CAP | 62332-0823-30 | 4.66112 | EACH | 2026-03-18 |
| DEXLANSOPRAZOLE DR 30 MG CAP | 49884-0147-11 | 4.66112 | EACH | 2026-03-18 |
| DEXLANSOPRAZOLE DR 60 MG CAP | 00378-2086-77 | 4.21355 | EACH | 2026-03-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
DEXLANSOPRAZOLE DR Market Analysis and Financial Projection
Market Landscape and Price Projections for Dexlansoprazole DR
Dexlansoprazole DR is a delayed-release proton pump inhibitor (PPI) indicated primarily for gastroesophageal reflux disease (GERD). It originated from Takeda Pharmaceuticals, with its patent protections. The drug competes within a mature PPI landscape, featuring key branded and generic options.
Market Size and Growth Dynamics
The global PPI market stood at approximately $15 billion in 2022, driven by GERD prevalence and chronic heartburn. Within this, Dexlansoprazole DR captured an estimated 5% market share in North America and Europe. The compound's approval in 2010 broadened options; however, it faces competition from omeprazole, esomeprazole, and rabeprazole.
Projections indicate the PPI market will grow at a compound annual growth rate (CAGR) of 4–5% over the next five years, driven by:
- Increased GERD prevalence (WHO reports 20–30% of populations affected worldwide)
- Aging populations with heightened need for acid suppression
- Emerging markets expanding prescription use
Patent and Patent Expiry Timeline
Takeda secured Dexlansoprazole's patent protection in key markets until 2024–2025. Patent expiries in major regions (US: 2024; EU: 2025) signal an eventual influx of generics. The expiration opens the market to generic competitors, which typically lead to substantial price reductions.
Competitive Landscape
- Branded Market Players: Takeda (original manufacturer)
- Generic Manufacturers: Several (e.g., Teva, Mylan, Sandoz), planning to launch or already selling generic versions post-patent expiry
- Other PPIs: Esomeprazole (Nexium), Omeprazole (Prilosec), Lansoprazole, all with established market presence
Pricing Structure and Trends
Branded Dexlansoprazole DR
- Average wholesale prices (AWP) in the US: $200–$250 for a 30-count supply of 30 mg capsules
- Patient co-pays vary; coverage often through insurance plans
Generic Versions
- Launch prices likely to be 50–70% lower than brand, with initial prices around $100–$150 per 30-day course
- Price erosion often accelerates within the first 12–18 months of generic market entry
Post-Patent Market Projections
| Year | Estimated Market Share | Price Range (per 30-day supply) | Comments |
|---|---|---|---|
| 2024 | 100% (generic entry) | $50–$100 | Entry of multiple generics drives competition |
| 2025 | 100% (generic dominance) | $40–$80 | Price stabilization with high competition |
| 2026–2030 | Dominate in outpatient settings | $30–$50 | Price consolidation expected; ongoing generics impact |
Revenue Projections
Assuming a conservative penetration of 50 million prescriptions annually in key markets, with an average per-unit revenue:
- Pre-patent expiry (2023): Revenue may range from $1–1.2 billion annually
- Post-patent expiry (2024+): Expected reduction by approximately 40–60%, leading to potential revenues of $600–700 million, considering increased volume from lower prices
Key Market Dynamics Influencing Pricing
- Therapeutic Equivalence: Confirmed for generics, supporting rapid price declines
- Market Penetration Speed: Usually within 12–24 months post-patent expiry
- Reimbursement Policies: May vary; US-centric models show prompt price reductions due to competitive tendering
Regulatory and Policy Impacts
Regulatory bodies facilitate generic approvals, leading to swift market entry. Price controls or negotiating strategies in specific countries might modify projections, especially in healthcare systems with strict price caps.
Key Takeaways
- Dexlansoprazole DR's patent protections end in 2024–2025, paving the way for generic versions.
- The global PPI market grows at 4–5% CAGR, driven by aging populations and GERD prevalence.
- Branded pricing averages $200–$250, with generics expected at $50–$100 post-expiry.
- Market share shifts rapidly toward generics within 12–18 months after patent expiration.
- Revenues could decline by up to 60%, but volume growth may partially offset price erosion.
FAQs
Q1: What are the main competitors to Dexlansoprazole DR?
Omeprazole, lansoprazole, esomeprazole, and rabeprazole are established alternatives within PPI therapy, with generics available for most.
Q2: When is Dexlansoprazole DR's patent expected to expire?
Most US patents expire in 2024, with EU patents ending in 2025, opening the market for generics.
Q3: How will generic entry affect drug pricing?
Prices are projected to decrease by 50–70%, reaching $40–$80 per month supply, over 12–24 months after patent expiry.
Q4: What factors could influence the timing of generic market entry?
Regulatory approval processes, patent litigation, and manufacturing scale-up can accelerate or delay generic launches.
Q5: How will market growth trends impact future revenues for Dexlansoprazole?
As the overall PPI market expands, the drug's share may decline temporarily post-patent expiry, but volume growth could sustain revenues.
Sources
- Market Research Future, "Proton Pump Inhibitors Market," 2022.
- IQVIA Institute, "The Global Use of Medicines in 2022," 2022.
- U.S. Patent and Trademark Office, patent expiry schedules.
- EvaluatePharma, "Topical & Gastroenterology Drugs," 2022.
- WHO, "Gastroesophageal Reflux Disease and Esophageal Disorders," 2021.
More… ↓
